Annexin Pharmaceuticals AB
- Biotech or pharma, therapeutic R&D
Annexin Pharmaceuticals is advancing a first in class biologic, ANXV (recombinant human Annexin A5), with a broad therapeutic potential. ANXV targets a cell surface lipid phosphatidylserine (PS) associated with various diseases. In an open label Ph2a/PoC study in treatment naive patients retinal vein occlusion (RVO), leading to severe visual impairment and chronic treatment requirements, excellent tolerability and clinically meaningful signals of effect are reported relating to visual acuity, macular edema, macular blood perfusion and impact on the need for chronic treatments. While RVO with a blockbuster potential is the lead indication, with Ph2b-planning ongoing, the company is expanding the ANXV asset into a Ph2 a/PoC study in diabetic retinopathy but also into cancer and sickle cell disease, indications where the role of ANXV´s target have been strongly implied by independent researchers.
The company is seeking partnerships in ophthalmology, cancer and sickle cell disease.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}